SCHEMBL4490748

SCHEMBL4490748

COC(=O)[C@H](N)Cc1cc(C)c(O)c(Cl)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
SLC7A5 Q01650 1/20 0.41
TDP1 Q9NUW8 1/20 0.38
CASR P41180 1/20 0.38
MRE11 P49959 1/20 0.38
THRB P10828 5/20 0.38
THRA P10827 4/20 0.38
MEN1 O00255 3/20 0.36
KMT2A Q03164 3/20 0.36
LMNA P02545 2/20 0.36
TTR P02766 2/20 0.36
ADORA3 P0DMS8 2/20 0.36
PDE4D Q08499 2/20 0.36
HSD17B10 Q99714 2/20 0.36
PTGS2 P35354 2/20 0.36
NR3C1 P04150 1/20 0.36
CYP1A2 P05177 1/20 0.36
HTR1A P08908 1/20 0.36
CYP2C9 P11712 1/20 0.36
TBXA2R P21731 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14032563 1.00 ALDH1A1 (0.41) ALDH1A1SLC7A5TDP1CASRMRE11
SCHEMBL5107901 1.00 ALDH1A1 (0.41) ALDH1A1SLC7A5TDP1CASRMRE11
Hydrochloric Acid SCHEMBL5107894 0.99 ALDH1A1 (0.43) ALDH1A1SLC7A5TDP1CASRMRE11
Hydrochloric Acid SCHEMBL5107895 0.99 ALDH1A1 (0.43) ALDH1A1SLC7A5TDP1CASRMRE11
SCHEMBL5115944 0.90 ALDH1A1 (0.46) ALDH1A1SLC7A5THRBTHRAMEN1
SCHEMBL5115950 0.90 ALDH1A1 (0.46) ALDH1A1SLC7A5THRBTHRAMEN1
Hydrochloric Acid SCHEMBL5776200 0.88 ALDH1A1 (0.48) ALDH1A1SLC7A5THRBTHRAMEN1
Hydrochloric Acid SCHEMBL5776197 0.88 ALDH1A1 (0.48) ALDH1A1SLC7A5THRBTHRAMEN1
SCHEMBL23387531 0.84 ALDH1A1 (0.49) ALDH1A1MEN1KMT2ALMNAMAPT
SCHEMBL30611522 0.84 ALDH1A1 (0.49) ALDH1A1MEN1KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528129-B2 CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-05-05 US disclosed
EP-1863799-A1 CGRP-ANTAGONISTS, PROCESS FOR THEIR PREPARATION AS WELL AS THEIR USE AS MEDICAMENTS Boehringer Ingelheim International GmbH (DE) 2007-12-12 EP disclosed
EP-1770091-A1 CGRP-antagonists, process for their preparation as well as their use as medicaments Boehringer Ingelheim Pharma GmbH & Co. KG (DE) 2007-04-04 EP disclosed
US-20060252931-A1 New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-11-09 US disclosed
WO-2006100009-A1 CGRP ANTAGONISTS, METHOD FOR THE PRODUCTION THEREOF, AND THEIR USE AS MEDICAMENTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060252931-A1 New CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions CALCRL, CALCR, CALCA ALDH1A1 1872/4885SLC7A5 957/4885TDP1 1021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.